A randomised, open label, Phase 3 study of Abemaciclib combined with standard adjuvant endocrine therapy alone in patients with high risk, node positive, early stage, hormone receptor positive, HER2 negative breast cancer.

The aim of this study, MonarchE, is to evaluate whether the combination of Abemaciclib plus standard adjuvant endocrine therapy improves outcomes in participants with a certain type of breast cancer compared to adjuvant endocrine therapy alone.

Abemaciclib is an oral drug which stops the production of proteins in the body called CDK4 and CDK6, which are responsible for promoting cell growth. This mechanism and Abemaciclib has been shown to have antitumour activity and significantly reduce tumour growth, including breast cancer.

This trial is specifically for patients (includes men as well as women) with node positive, early stage, hormone receptor positive, HER2 negative, invasive breast cancer and are at high risk of disease recurrence.

New Zealand centres for this trial are Auckland City, Waikato and Palmerston Hospitals. If you think you might be eligible to participate in this trial please speak with your medical team.